RAJWINDER KAUR: Open Payments
NPI 1083265565 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,150 in 44 payments from 14 companies in 2025. Trend: 2023 $1,481 · 2024 $1,208 · 2025 $1,150
Food & beverage: $1,150
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $275 |
| Amgen Inc. | 7 | $138 |
| GENZYME CORPORATION | 1 | $118 |
| Verona Pharma, Inc. | 4 | $117 |
| GlaxoSmithKline, LLC. | 5 | $109 |
| United Therapeutics Corporation | 4 | $88 |
| Actelion Pharmaceuticals US, Inc. | 3 | $76 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $55 |
| Electromed, Inc. | 3 | $48 |
| Insmed, Inc. | 2 | $44 |
Products named: TEZSPIRE, DUPIXENT, Ohtuvayre, FASENRA, Tyvaso, AIRSUPRA, NUCALA, OPSUMIT.
Industry payments across CA — which companies pay providers there.
